Kringle Pharma, Inc.

July 31, 2018 Kringle Pharma successfully raised 200 million JPY in funding from THVP-1 Fund (General Partner: Tohoku University Venture Partners Co., Ltd.).

June 1, 2018 Kringle’s recombinant human HGF is now available as a research reagent at REPROCELL, Inc. For more information, please contact REPROCELL, Inc. through their website as follows.

May 11, 2018 Kringle Pharma announces that the last subject has completed the follow-up period after dosing in the Phase I/II study of recombinant human HGF for acute spinal cord injury.

February 27, 2018 A patent entitled 'HGF preparation suitable for treatment of nervous diseases' was granted in Japan. Patent No. JP6281992.

January 10, 2018 Clinical data from the investigator-initiated Phase I/II of recombinant human HGF for treatment of vocal fold scar were published in Journal of Tissue Engineering and Regenerative Medicine (25 DEC 2017, DOI: 10.1002/term.2603). It was demonstrated that intracordal injection of the recombinant human HGF drug was safe, feasible, and potentially effective for vocal fold scar patients based on several evaluation methods.

Copyright (C)2004-2011 Kringle Pharma, Inc. All rights reserved.